The Mississauga expansion adds 627 square feet of flexible laboratory space for process development and manufacturing of high-potency and non-high-potency APIs.
The agreement targets initial GMP exosome batches in the first half of 2027 to support NurExone’s clinical pipeline and potential commercial production.
This episode of Off Script, sponsored by Saint-Gobain Critical Process Solutions, looks into how filtration influences biopharmaceutical manufacturing processes.
